U.S. markets open in 1 hour 19 minutes

Amgen's Multiple Myeloma Drug Shows Promise in Phase 3 Trial


Shares of Amgen are moving higher on Monday. The drug maker is seeing great signs in the development of treatment for multiple myeloma, a bone marrow cancer. The results from its Phase 3 of Kyprolis' clinical trial shows that patients can live almost nine months longer without worsening symptoms. According to Amgen, about 70,000 people in the U.S. are living with the disease and 24,000 new cases are diagnosed every year. With the good clinical trial result, Amgen plans to begin regulatory submissions around the world next year. Dr. Pablo Cagnoni, president of Amgen's subsidiary Onyx Pharmaceuticals said, "The results demonstrate that Kyprolis can significantly extend the time patients live without their disease progressing. The ability of novel therapies to produce deep and durable responses may, one day, transform this uniformly fatal disease to one that is chronic and manageable." Male patients over the age of 65 have the highest risk of developing it.